Material Agreement · Company Update

Ligand Pharmaceuticals Incorporated entered into a Fourth Amendment to its Credit Agreement to permit a proposed offering of convertible senior notes and amended financial covenants. The company also announced its intent to offer $550 million aggregate principal amount of these notes.